Private Equity Funded Biotechnology Startups
The 25 private equity rounds in this view span biotechnology companies across the US, UK, continental Europe, and Switzerland, with closing dates running f…
The 25 private equity rounds in this view span biotechnology companies across the US, UK, continental Europe, and Switzerland, with closing dates running from August 2021 through late October 2022. Disclosed amounts range from $100K entries such as BioEcho Life Sciences (Cologne) and ten23 health (Basel) up to $100M raised by Dianthus Therapeutics (Waltham, Massachusetts), with F2G (Manchester) and iProov (London) each at $70M. Nine of the 25 rounds list amounts as undisclosed, consistent with standard PE confidentiality norms.
US companies account for the majority, with clusters in Massachusetts — Lykan BioScience, Cynosure, and Dianthus Therapeutics — as well as California (AnaBios, Claritas Pharmaceuticals) and Pennsylvania (Automation & Validation Solutions, ZenQMS). European companies represent a substantial minority: the UK contributes four entries across Manchester, Oxford, and London, while Germany adds three (including Isotopen Technologien München at $36M) and Switzerland two.
Most recent rounds
25 shownRelated listings
Frequently asked
What are the largest disclosed PE rounds among these biotech companies?
Dianthus Therapeutics (Waltham, Massachusetts) leads at $100M, closed in April 2022. F2G (Manchester) and iProov (London) both raised $70M, in August and January 2022 respectively. Cynosure (Westford, Massachusetts) closed a $60M round in May 2022, followed by Angiocrine Bioscience (New York) at $58M in October 2021 and Protix Biosystems (Dongen, Netherlands) at $57M in February 2022.
How many of these rounds disclosed their deal size?
16 of the 25 rounds include a disclosed amount; the remaining 9 — including CitiusTech, Corium, Lykan BioScience, and Clearwave — report undisclosed terms. Among disclosed rounds, the range is wide: from $100K (BioEcho Life Sciences, BioMedion, Resonetics, ten23 health) to $100M (Dianthus Therapeutics).
Which US states have the most PE-backed biotech companies in this dataset?
Massachusetts and California each appear three times. Massachusetts includes Lykan BioScience (Hopkinton), Cynosure (Westford), and Dianthus Therapeutics (Waltham); California includes AnaBios (San Diego), Sequoia (Encinitas), and Claritas Pharmaceuticals (San Rafael). New Jersey and Pennsylvania each contribute two companies.
How significant is European representation in this PE biotech segment?
11 of the 25 companies are headquartered in Europe. The UK leads with four entries — F2G (Manchester), Mirada Medical (Oxford), iProov (London), and GENinCode (Oxford). Germany adds three (Isotopen Technologien München, BioEcho Life Sciences, BioMedion), Switzerland two (Eulitha, ten23 health), and France and the Netherlands one each.
What timeframe do these 25 rounds cover, and is activity concentrated in any particular period?
The rounds span August 2021 to October 2022, roughly 14 months. Activity is heavily weighted toward 2022, with 20 of the 25 rounds closing in that calendar year. October 2022 is the most active single month in the dataset, accounting for five closings.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.